• Users Online: 380
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 191

Adjuvant pembrolizumab in renal cell carcinoma


Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Date of Submission10-Jan-2022
Date of Decision22-Jan-2022
Date of Acceptance23-Jan-2022
Date of Web Publication24-Feb-2022

Correspondence Address:
Ajay Gogia
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_10_22

Rights and Permissions

How to cite this article:
Raodha R, Gogia A, Baa A. Adjuvant pembrolizumab in renal cell carcinoma. Cancer Res Stat Treat 2022;5:191

How to cite this URL:
Raodha R, Gogia A, Baa A. Adjuvant pembrolizumab in renal cell carcinoma. Cancer Res Stat Treat [serial online] 2022 [cited 2022 May 21];5:191. Available from: https://www.crstonline.com/text.asp?2022/5/1/191/342436



Choueiri et al.[1] have recently reported the benefit of adjuvant pembrolizumab for high-risk renal cell carcinoma (RCC) with a significant increase in the disease-free survival (DFS) compared to placebo. A subgroup analysis showed a significant DFS benefit of pembrolizumab in patients younger than 65 years of age and programmed death-ligand 1 (PD-L1) combined positive score (CPS)>1. This might be due to the occurrence of age-dependent changes in patients older than 65 years of age that include a reduced level of PD-L1 along with other immune modulation.[2],[3],[4] The median age of diagnosis of RCC in real-world settings is 65 years,[5],[6] hence it would be interesting to know how many patients aged over 65 years had PD-L1 CPS >1 and what their outcomes were. The adverse events (AEs) of adjuvant pembrolizumab and the drug discontinuation rate (DDR) were substantially higher as compared to placebo (AE grade 3–5, 32.4% vs. 17%, DDR, 20.7% vs. 2%, respectively). In view of the significant toxicity, modest improvement in overall survival, and no clinically significant difference in patient-reported outcomes (defined arbitrarily), adjuvant pembrolizumab should be used very cautiously.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:683-94.  Back to cited text no. 1
    
2.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res 2020;10:727-42.  Back to cited text no. 2
    
3.
Abraham G, Jobanputra KN, Noronha V, Patil VM, Menon NS, Gattani SC, et al. Immune checkpoint inhibitors in older patients with solid tumors: Real-world experience from India. Cancer Res Stat Treat 2021;4:270-6.  Back to cited text no. 3
  [Full text]  
4.
Arora S, Kumar L. Immune checkpoint inhibitors in older patients with cancer: A new era in cancer therapy. Cancer Res Stat Treat 2021;4:368-9.  Back to cited text no. 4
  [Full text]  
5.
Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma. JAMA Netw Open 2021;4:e2111329.  Back to cited text no. 5
    
6.
Abbas W, Aggarwal A, Pankaj P, Jain R. Real-world data of second-line immunotherapy in metastatic clear cell renal cell carcinoma: A retrospective study. Cancer Res Stat Treat 2021;4:55-60.  Back to cited text no. 6
  [Full text]  




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed172    
    Printed6    
    Emailed0    
    PDF Downloaded10    
    Comments [Add]    

Recommend this journal